WHO ICTRP trial
Intranasal administration of oxytocin in children with Prader-Willi Syndrome
EUCTR2016-003820-22-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2016-003820-22-NL |
|---|---|
| Public title | Intranasal administration of oxytocin in children with Prader-Willi Syndrome |
| Scientific title | Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating behaviour and social behaviour. - Intranasal administration of oxytocin in children with PWS |
| Primary sponsor | Dutch Growth Research Foundation |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Prader-Willi syndrome MedDRA version: 19.0 Level: PT Classification code 10036476 Term: Prader-Willi syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Hormonal diseases… |
| Interventions | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin Pharmaceutical Form: Nasal spray |
| Registration date | Dec 10, 2016 |
| Secondary IDs | 2016-Longterm-OX |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: